BioCentury | Oct 17, 2019
Financial News

Oct. 16 Financial Quick Takes: Hong Kong IPO could value Ascentage at $876M; plus Principia, Rhythm, ProQR, dMed, Ionova and Amarna

...raised €10 million ($11 million) in a private offering, which will enable it to bring SVac...
BioCentury | Aug 3, 2015
Company News

Amarna Therapeutics, CBMed deal

...lymphoblastic leukemia (ALL), obesity, Type II diabetes and atherosclerotic cardiovascular disease. Amarna will provide its SVac...
...will utilize SVac expressing a chimeric antigen receptor (CAR) against CD19 to treat ALL and SVac...
Items per page:
1 - 2 of 2